266 related articles for article (PubMed ID: 25498507)
1. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.
Rossi G; Carella AM; Minervini MM; di Nardo F; Waure Cd; Greco MM; Merla E; Cillis GP; Di Renzo N; Melpignano A; Capalbo S; Palumbo G; Pisapia G; Cascavilla N
Leuk Res; 2015 Feb; 39(2):138-43. PubMed ID: 25498507
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
3. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.
Miyazaki T; Fujita H; Fujimaki K; Hosoyama T; Watanabe R; Tachibana T; Fujita A; Matsumoto K; Tanaka M; Koharazawa H; Taguchi J; Tomita N; Sakai R; Fujisawa S; Kanamori H; Ishigatsubo Y
Leuk Res; 2012 Aug; 36(8):998-1003. PubMed ID: 22551655
[TBL] [Abstract][Full Text] [Related]
8. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels.
Rossi G; Minervini MM; Melillo L; di Nardo F; de Waure C; Scalzulli PR; Perla G; Valente D; Sinisi N; Cascavilla N
Ann Hematol; 2014 Jul; 93(7):1149-57. PubMed ID: 24554303
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
10. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
[TBL] [Abstract][Full Text] [Related]
11. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
[TBL] [Abstract][Full Text] [Related]
12. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
13. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
15. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
[TBL] [Abstract][Full Text] [Related]
16. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
Duléry R; Nibourel O; Gauthier J; Elsermans V; Behal H; Coiteux V; Magro L; Renneville A; Marceau A; Boyer T; Quesnel B; Preudhomme C; Duhamel A; Yakoub-Agha I
Bone Marrow Transplant; 2017 Apr; 52(4):539-543. PubMed ID: 28067876
[TBL] [Abstract][Full Text] [Related]
17. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
Frairia C; Aydin S; Audisio E; Riera L; Aliberti S; Allione B; Busca A; D'Ardia S; Dellacasa CM; Demurtas A; Evangelista A; Ciccone G; Francia di Celle P; Nicolino B; Stacchini A; Marmont F; Vitolo U
Leuk Res; 2017 Oct; 61():10-17. PubMed ID: 28846953
[TBL] [Abstract][Full Text] [Related]
18. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
[TBL] [Abstract][Full Text] [Related]
19. Correlation of minimal residual disease by assessing Wilms tumor gene expression and engraftment by variable number of tandem repeats in children with leukemia posthematopoietic stem cell transplantation.
Olszewski M; Chou PM; Huang W; Tallman S; Kletzel M
Pediatr Dev Pathol; 2006; 9(3):203-9. PubMed ID: 16944968
[TBL] [Abstract][Full Text] [Related]
20. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
